Navigation Links
Gene Network Sciences Announces Drug Development Collaboration with Biogen Idec

CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has entered into an agreement with Biogen Idec under which GNS will use its proprietary REFS(TM) software platform to process clinical data provided by Biogen Idec to identify targets and biomarkers in inflammation. A forward simulation model generated directly from the Biogen Idec data will be licensed to Biogen Idec at the conclusion of this project. Financial terms of the agreement were not disclosed.

GNS employs massively parallel supercomputers to probe vast amounts of raw human biological data to discover new insights into the biological causes of human disease, and new opportunities for diagnosis and treatment. Under this agreement, GNS will use its REFS(TM) (Reverse Engineering/Forward Simulation) platform to transform genetic, genomic, and clinical data provided by Biogen Idec to generate and score billions of hypotheses to discover new drug targets and biomarkers rapidly.

"Our proprietary technology is capable of taking raw 'omic' data and running billions of calculations in a short period of time to find potential biomarkers and promising drug targets that could lead to more effective patient treatments," said Colin Hill, CEO of GNS. "It is the value and speed of our REFS(TM) technology and the potential it offers to the Biogen Idec drug development program that forged our partnership."

About REFS(TM)

Reverse Engineering/Forward Simulation (REFS(TM)) is a technology that systematically turns multiple layers of biologically relevant data into an unprecedented view of human biology and disease as a "whole." REFS(TM) begins with raw biological data (genetic, genomic, epigenetic, proteomic, metabolomic and environmental) and rapidly performs billions upon billions of calculations to determine how the molecules interact with one another in the complete system (Reverse Engineering). These computer-assembled models are then queried rapidly through billions of in silico experiments (Forward Simulation) to discover the highest-impact molecular targets for the disease being studied and the corresponding efficacy and toxicity markers related to specific drug treatments. These findings are then tested in both the laboratory and the clinic, enabling a faster, more focused and more effective drug discovery and development process.

About Gene Network Sciences

Founded in 2000, Gene Network Sciences ( is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data without any a priori knowledge. Headquartered in Cambridge, Massachusetts, GNS uses its REFS(TM) (reverse engineering and forward simulation) technology in pharmaceutical and clinical settings to rapidly turn complex and heterogeneous data sets into cell and organ-level computer models of disease biology, drug efficacy and drug safety. These models simulate mechanisms of disease and the clinical performance of drug candidates. By discovering how and why specific drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

For more Information, please contact:

Lynn Blenkhorn Thomas Neyarapally

Feinstein Kean Healthcare Gene Network Sciences, Inc.

508-851-0930 617-494-0492

SOURCE Gene Network Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Access Innovations Provides Support Services for Agis Network
2. Womens World Banking Welcomes New Network Member From Tunisia
3. Internet TV Network for Personal Trainers is Launched
4. Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right
5. Guardians Dental Network Experiences Double-Digit Growth
6. Chronic infection persists by targeting stromal cell network in lymphoid organs
7. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
8. Blue Care Network of Michigan Earns National Leadership Award for Chronic Disease Management
9. AT&T Offers Network Industry-First RFID Solution for Health Care Organizations
10. AT&T Establishes New Network Services for Leading Medical Liability Insurer
11. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: